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ABSTRACT
Objective Genetic sonography following first-trimester
combined screening appears to increase substantially
detection rates for Down syndrome but it relies on
the unproved assumption of independence between these
tests. In this study we aimed to investigate the relationship
between first-trimester nuchal translucency (NT) and a
series of second-trimester soft markers and structural
defects in unaffected pregnancies.
Methods NT measurement in the first trimester was
followed by second-trimester scan (18 to 23 + 6 weeks)
including examination for three categorical markers
(intracardiac echogenic foci, hyperechogenic bowel and
structural defects) and measurement of nasal bone length,
nuchal-fold thickness, femur length, humerus length, renal
pelvis diameter and prenasal thickness. All continuous
variables were expressed in multiples of the median
(MoM) for gestation and correlation coefficients between
log-transformed NT and second-trimester variables were
calculated. In addition, frequencies of soft markers and
structural defects in cases with increased NT were
compared to those with normal NT, using MoM cut-offs.
Results In a dataset of 1970 cases, NT was significantly
correlated (P < 0.05) with all second-trimester continuous
variables, the correlation being strongest for nuchal-fold
thickness (r = 0.10). There was a higher frequency of
cases with second-trimester nuchal-fold thickness above
the 97.5th centile (10.7 vs. 2.2%) and hyperechogenic
bowel (2.4 vs. 0.1%) in cases with increased NT.
Conclusions Straightforward reassessment of risk using
likelihood ratios derived from the second-trimester genetic
sonogram might lead to inaccurate estimates. Multivariate
models using continuous second-trimester variables might
be preferable in sequential screening strategies. Copyright
 2012 ISUOG. Published by John Wiley & Sons, Ltd.
INTRODUCTION
Down syndrome screening has shifted from the second
to the first trimester in recent years. First-trimester
combined screening offers both better performance and
the advantages of providing earlier reassurance or a safer
termination of pregnancy, if required1–3. Nevertheless,
first-trimester sonography has not obviated the need for a
second-trimester scan to exclude major structural defects
and other recognizable complications of pregnancy4.
During second-trimester sonography, a series of ‘soft
markers’ or major structural defects are reported in
70–75% of Down syndrome cases4–6. The presence
or absence of such findings can be used to modify
the background risk by applying positive or negative
likelihood ratios4–6. The use of this approach in sequential
screening strategies, both in models7 and in prospective
interventional studies8–10, has resulted in identification of
about 50% of Down syndrome cases that had remained
undetected following first-trimester combined screening,
with minimal impact on false-positive rates7–10.
The use of second-trimester likelihood ratios relies
on the assumption of independence between first- and
second-trimester markers, an assumption that has not
been fully investigated4. In fact, it would be reasonable to
expect some kind of relationship between them. Cardiac
defects and echogenic foci, for instance, are known to be
associated with increased nuchal translucency (NT)11,12.
On the other hand, NT and second-trimester nuchal-
fold thickness, despite presumably sharing a similar
pathophysiology, were not found to be related in three
independent studies13–15.
More recently, theoretical models incorporating highly
discriminatory soft markers (nuchal-fold thickness, nasal
bone length and prenasal thickness) have predicted even
higher detection rates (81% for a 5% false-positive
rate)16–19. However, correlations between these second-
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and first-trimester markers have not been described,
precluding their incorporation into sequential screening
protocols.
In this study we investigated the relationship between
first-trimester NT and a series of second-trimester soft
markers and structural defects in unaffected pregnancies,
in order to obtain reliable parameters for planning
sequential screening strategies.
METHODS
This was a prospective cohort study including viable sin-
gleton pregnancies, scanned from 11 to 13 + 6 weeks’
gestation (crown–rump length (CRL) 45–84 mm) from
August 2007 to December 2009 at the University of Sa˜o
Paulo Obstetrics and Gynecology Department. Informed
consent was obtained in all cases and the study was
approved by the local ethics committee.
NT measurement was performed by Fetal Medicine
Foundation-accredited examiners, using previously des-
cribed guidelines20. Three different ultrasound machines
were used: Voluson 730 Expert (GE Healthcare, Mil-
waukee, WI, USA), Voluson 730 Pro (GE Healthcare)
and Envisor (Philips Healthcare, Eindhoven, The Nether-
lands). Gestation was dated based on CRL21, and all
patients were offered a second appointment for an
anomaly scan between 18 and 23 + 6 weeks. Follow-up
was obtained by letter, phone contact or search in the
local cytogenetic database or hospital medical records.
Exclusion criteria were: cases showing major structural
defects during the first-trimester scan; prenatal or post-
natal diagnosis of chromosomal abnormalities; failure to
return at 18 to 23 + 6 weeks; pregnancy loss at any stage;
lack of follow-up; and stillbirth.
The second-trimester ultrasound examiners were
blinded to the first-trimester results. Second-trimester fetal
anatomical survey was followed by a search for a num-
ber of soft markers, including categorical and continuous
variables, evaluated using previously described standard
techniques4–6,9,19,22. Categorical variables were: presence
or absence of intracardiac echogenic foci (in the apical
four-chamber view), hyperechogenic bowel (as bright as
the iliac bone) and structural defects. Continuous vari-
ables were: nasal bone length, nuchal-fold thickness,
femur and humerus length, largest renal pelvis antero-
posterior diameter and prenasal thickness.
All continuous variable measurements, including first-
trimester NT, were converted into multiples of the
gestation-specific normal median (MoMs) using previ-
ously described techniques23,24. In short, fetuses were
divided into 12 roughly equal gestational-age (GA) groups
and the median in each group was regressed against the
median GA, weighted by the number of women in that
group. NT measurements were converted into MoMs
using regression of the medians for the nearest integer
CRL value. The best-fit polynomial regression model
for each variable was chosen and medians were log-
transformed if appropriate. Standard deviations (SD) for
log-transformed MoM variables were estimated robustly,
by the 90th –10th centile range divided by 2.56323.
Log-transformed NT-MoMs were then plotted against
log-transformed continuous variable MoMs. Whenever a
statistically significant correlation was found (P ≤ 0.05) ,
the Pearson correlation coefficient was calculated. Mea-
surements less than or greater than 3 SD from the median
were excluded to avoid interference of extreme values
(outliers) on the correlation coefficient.
Statistical analysis was performed using ‘Analyse-it
standard-edition’ (Analyse-it Software, Ltd, Leeds, UK),
an add-in software for Microsoft Excel (Microsoft, Red-
mond, USA). The minimum sample size necessary for
finding a significant correlation coefficient was calculated,
assuming a small effect size (r = 0.10) for an 80% power
and a 0.05 alpha risk, as being 783 cases25.
Subsequently, the frequency of soft markers (increased
nuchal-fold thickness, renal pyelectasis, short femur, short
humerus, hyperechogenic bowel, echogenic focus) and
structural defects in the group with increased NT (above
the 95th centile) was compared with the group with nor-
mal NT (Fisher’s or chi-square test), using MoM cut-offs:
2.5th (short femur or humerus) or 97.5th centiles (nuchal
fold and renal pelvis).
RESULTS
From the initial population of 2257 pregnancies there
were 287 exclusions, resulting in a final dataset of 1970
cases. Reasons for exclusions were: failure to return
for the 18 to 23 + 6-week scan (n = 131), pregnancy
loss/stillbirth (n = 63), no postnatal follow-up (n = 55),
first-trimester major abnormalities (n = 20), chromoso-
mal abnormalities (n = 17) and bilateral renal agenesis
(n = 1).
First-trimester scan was performed from 11 to 11 +
6 weeks in 19.4%, from 12 to 12 + 6 weeks in 52.8%
and from 13 to 13 + 6 weeks in 27.8%. Median CRL
was 61.8 mm and median NT 1.65 mm, which was
0.04 mm below the expected median according to the
Fetal Medicine Foundation algorithm26. NT measurement
medians fitted a quadratic regression model well (NT =
−1.641 + (0.08325 × GA) − (0.0004927 × GA2)). After
MoM conversion, NT median was 0.9957 and log10SD
was 0.0904.
Second-trimester scan was performed from 18 to
19 + 6 weeks in 20.9%, from 20 to 21 + 6 weeks in
71.2% and from 22 to 22 + 6 weeks in 7.9% of cases.
All MoM-converted continuous-variable medians (nasal
bone length, femur length, humerus length, largest renal
pelvis, prenasal thickness and nuchal-fold thickness) were
close to 1.0 and fitted a log-normal distribution as assessed
by histograms and QQ plots. Table 1 summarizes their
distribution parameters. A statistically significant corre-
lation between log NT-MoMs and all second-trimester
continuous variables was found (Table 1). The Pearson
correlation coefficient was then calculated for each vari-
able. This was low in all cases (Table 1), the highest being
that of nuchal-fold thickness (r = 0.10; Figure 1).
Copyright  2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 39: 274–278.
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Table 1 Distribution parameters of continuous variables, correlation coefficients between log-transformed second-trimester markers
(expressed as multiples of the median (MoM)) and log-transformed first-trimester nuchal translucency thickness (MoMs) and their respective
level of significance
Marker n
Mean
(mm)
Median
(MoM)
log10SD
(MoM)
Correlation
coefficient (95% CI) P
Nasal bone length (NB) 1957 5.82 0.9956 0.0537 −0.05 (−0.09 to −0.002) 0.043
Femur length (FL) 1970 33.4 0.9986 0.0225 0.05 (0.01 to 0.10) 0.017
Humerus length (HL) 1888 32.0 0.9965 0.0242 0.05 (0.002 to 0.09) 0.041
Largest renal pelvis (RP) 1889 2.4 1.0018 0.1857 0.07 (0.03 to 0.12) 0.002
Prenasal thickness (PT) 1062 3.4 1.0048 0.0687 0.09 (0.03 to 0.15) 0.005
Nuchal fold thickness (NF) 1970 4.1 1.0039 0.0796 0.10 (0.06 to 0.15) < 0.001
MoMs were computed from regressed medians for gestational age (GA) (weeks): NB = 10∧(0.9639 − (0.0468 × GA) + (0.001792 × GA2));
FL = −76.41 + (7.971 × GA) − (0.1279 × GA2); HL = −43.57 + (4.964 × GA) − (0.06246 × GA2);
RP = −15.73 + (1.654 × GA) − (0.03795 × GA2); PT = −2.543 + (0.2888 × GA); NF = 0.578 + (0.06403 × GA) + (0.005201 × GA2).
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Figure 1 Scatterplot of first-trimester nuchal translucency thickness
vs. second-trimester nuchal-fold thickness (given as log-transformed
multiples of the median (MoM) for gestation), showing a small
(r = 0.10) although significant (P < 0.001) positive correlation.
The relationship between NT in the first trimester and
nuchal-fold thickness in the second was further demon-
strated by the higher frequency of cases (P < 0.01) with
second-trimester nuchal edema (> 97.5th centile) in the
group of fetuses with increased NT (Table 2): 10.7%
(9/84) vs. 2.2% (41/1886). The same was true (P < 0.01)
when we used a 6-mm nuchal-fold cut-off: 7.1% (6/84) vs.
0.9% (17/1886).
Hyperechogenic bowel was also found to be more fre-
quent (P = 0.02) in cases with increased NT (Table 2).
The frequency of other classical soft markers did not
diverge significantly among cases with normal or increased
NT. However, the presence of at least one marker was sig-
nificantly more prevalent (30.8 vs. 15.5%) in cases with
increased NT (Table 2).
DISCUSSION
The present study has demonstrated a relationship
between first-trimester NT and a series of second-trimester
soft markers, the most significant of which was nuchal-
fold thickness. Despite the correlation coefficient being
only 0.10, this resulted in a 4–5-fold increase in the
number of cases with increased nuchal-fold thickness in
the group with NT above the 95th centile.
These findings have major implications for sequen-
tial screening strategies involving second-trimester sono-
graphy. Previous studies have speculated that second-
trimester nuchal-fold edema and first-trimester NT
may represent a different underlying etiology, allow-
ing a straightforward reassessment of risk using
likelihood ratios derived from previously unscreened
populations13–15. These studies showed no significant
correlation between NT and nuchal fold but they lacked
the power to exclude a small correlation coefficient13–15.
The results from this study suggest that modifying first-
trimester Down-syndrome risk by using fixed likelihood
ratios derived from the second-trimester genetic sonogram
findings may lead to inaccurate estimates. This calculation
depends critically on the assumption that the first-
trimester markers and the anomaly scan results are
independent predictors of risk. The fact that the presence
of soft markers was twice as common in cases with
increased NT implies that this assumption is incorrect.
In fact, none of the classical soft markers seemed to
be independent of the first-trimester scan: nuchal edema
and echogenic bowel were found in this study to be
more prevalent in fetuses with increased NT. Other
continuous soft markers (femur and humerus length
and renal pelvis diameter) were found to be positively
correlated with first-trimester NT. The remaining two
markers (structural defects and echogenic focus) have
previously been linked to increased NT. Cardiac defects
are known to be associated with markedly enlarged NT11.
Similarly, echogenic foci were found, in a large series
involving 259 fetuses with NT above the 95th centile, to
be statistically more prevalent in such fetuses (8.1%) than
in those with normal NT (2.9%)12. The fact that our study
failed to demonstrate such associations could be because
of an insufficient number of cases with an increased NT
(n = 84).
Concerns about the validity of using genetic sonogram
likelihood ratios to modify first-trimester results are
further exacerbated by their lack of standardization.
In fact, there are wide variations in the definition of
individual markers and in the reported likelihood ratios
Copyright  2012 ISUOG. Published by John Wiley & Sons, Ltd. Ultrasound Obstet Gynecol 2012; 39: 274–278.
Second-trimester soft markers in unaffected pregnancies 277
Table 2 Comparison of second-trimester soft-marker frequencies in cases with normal nuchal translucency (NT) and in those with increased
NT (> 95th centile), stratified according to whether NT was < or ≥ 3 mm
Frequency in cases with NT > 95th centile
Marker
Frequency in cases with
normal NT (≤ 95th centile)
NT > 95th
centile
NT from 95th
centile to 2.9 mm NT ≥ 3.0 mm P*
Nuchal edema (> 97.5th percentile) 41/1886 (2.2) 9/84 (10.7) 3/61 (4.9) 6/23 (26.1) < 0.01†
Short humerus (< 2.5th percentile) 46/1886 (2.4) 2/82 (2.4) 1/59 (1.7) 1/23 (4.3) 1.00
Short femur (< 2.5th percentile) 46/1886 (2.4) 4/84 (4.8) 4/61 (6.6) — 0.32
Renal pyelectasis (> 97.5th percentile) 44/1810 (2.4) 4/79 (5.1) 3/58 (5.2) 1/21 (4.8) 0.28
Intracardiac echogenic focus 180/1885 (9.5) 9/84 (10.7) 8/61 (13.1) 1/23 (4.3) 0.72†
Hyperechogenic bowel 2/1886 (0.1) 2/84 (2.4) 2/61 (3.3) — 0.02
Structural defect 16/1886 (0.8) 1/84 (1.2) — 1/23 (4.3) 1.00
Any finding 272/1750 (15.5) 24/78 (30.8) 17/57 (29.8) 7/21 (33.3) < 0.01†
Data given as n (%). *Comparisons between cases with normal NT and cases with NT > 95th centile only; Fisher’s test used except where
indicated. †Chi-square test.
associated with each of these markers, individually or
in combination27. The examination is largely subjective,
therefore it is difficult to ensure quality.
Lau and Evans27 argued that second-trimester sono-
graphic screening programs should focus on the evalu-
ation of a few strong markers. Most soft markers are
too weak or subjective to be useful in the post first-
trimester screening era. Some more recently described
second-trimester soft markers – nasal bone length and
prenasal thickness – along with nuchal-fold thickness
seem to be a better choice16. These are all objective,
simple measurements that can be interpreted as continu-
ous variables, and are, therefore, amenable to external
audit and quality assurance. It has been shown that
these markers, like NT, are best expressed in MoMs
and likelihood ratios calculated continuously from a log-
Gaussian distribution17,28,29. Statistical modeling using
nasal bone length, prenasal thickness and nuchal-fold
thickness has predicted large detection rates and, if con-
firmed in prospective studies, this would have important
implications for health planners16.
This study also found some correlation between first-
trimester NT and both prenasal thickness and nasal bone
length. Although independency between the first and sec-
ond trimesters is necessary for interpreting these variables
dichotomously (with an increase defined against a fixed
cut-off in millimeters), multivariate Gaussian techniques
have long been used to deal with correlations between
variables in multimarker serum screening, and this does
not preclude their use in sequential screening17. In fact, it is
widely thought that correlations between screening mark-
ers will tend to degrade screening performance. However,
recent evidence has demonstrated that these correlations
can either decrease or increase screening performance,
provided a multivariate model is used30. In practice, these
effects are usually modest, because most screening mark-
ers are not highly correlated with each other30.
In conclusion, the findings of this study have two
important practical implications. First, we should be
cautious about re-evaluation of the risk assessed in
the first trimester based on the currently published
second-trimester sonographic-marker likelihood ratios,
as this could result in inaccurate estimates. Second, reli-
able sequential screening strategies involving sonographic
markers would almost certainly require multivariate risk
analysis.
The present study has provided all the necessary
parameters in unaffected pregnancies (median, SDs and
correlation coefficients) to construct a multivariate risk
model involving first-trimester NT, second-trimester nasal
bone length, prenasal thickness and nuchal-fold thickness.
However, more information is needed on correlations
between these variables and other first-trimester markers
in both normal and Down syndrome fetuses, to evaluate
how they might be incorporated into contingent screening
protocols.
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